Drug
LU Af35700
LU Af35700: highest development phase Phase 3, developed by Lundbeck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lu AF35700 NCT03230864 | Phase 3 | Treatment-resistant Schizophrenia |
Latest
No recent events.
Follow LU Af35700 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.